Processa Pharmaceuticals (PCSA) Total Current Liabilities (2012 - 2026)
Processa Pharmaceuticals' (PCSA) quarterly Total Current Liabilities came in at $2.0 million in Q1 2026, up 54.34% YoY from $1.3 million in Q1 2025, and down 11.45% on a QoQ basis from $2.2 million in Q4 2025.
Processa Pharmaceuticals (PCSA) Total Current Liabilities (2012 - 2026) Analysis & Trends
Processa Pharmaceuticals (PCSA) has 15 years of Total Current Liabilities data on file, last reported at $2.0 million in Q1 2026.
- Quarterly Total Current Liabilities rose 54.34% year-over-year to $2.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.0 million (up 54.34% YoY) and the FY2025 annual result came in at $2.2 million, up 45.91% from the prior year.
- Total Current Liabilities fell to $2.0 million in Q1 2026, from $2.2 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $2.2 million in Q4 2025 to a low of $730579.0 in Q4 2023.
- A 5-year average of $1.4 million and a median of $1.3 million in 2025 frame the typical range for Total Current Liabilities.
- The widest YoY moves for Total Current Liabilities: up 109.78% in 2024, down 53.23% in 2024.
- Tracing PCSA's Total Current Liabilities over 5 years: stood at $998556.0 in 2022, then decreased by 26.84% to $730579.0 in 2023, then surged by 109.78% to $1.5 million in 2024, then soared by 45.91% to $2.2 million in 2025, then decreased by 11.45% to $2.0 million in 2026.
- The last three Total Current Liabilities figures came in at $2.0 million (Q1 2026), $2.2 million (Q4 2025), and $1.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.51 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 438.74 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 630.93 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 2.49 Bn |
| 10 | Processa Pharmaceuticals | 5.93 Mn | 5.93 Mn | - | 2.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.98 Mn |
| Dec 31, 2025 | 2.24 Mn |
| Sep 30, 2025 | 1.75 Mn |
| Jun 30, 2025 | 2.07 Mn |
| Mar 31, 2025 | 1.28 Mn |
| Dec 31, 2024 | 1.53 Mn |
| Sep 30, 2024 | 1.22 Mn |
| Jun 30, 2024 | 1.55 Mn |
| Mar 31, 2024 | 1.01 Mn |
| Dec 31, 2023 | 730,579.00 |
| Sep 30, 2023 | 826,070.00 |
| Jun 30, 2023 | 821,414.00 |
| Mar 31, 2023 | 2.16 Mn |
| Dec 31, 2022 | 998,556.00 |
| Sep 30, 2022 | 1.19 Mn |
| Jun 30, 2022 | 1.57 Mn |
| Mar 31, 2022 | 1.06 Mn |
| Dec 31, 2021 | 971,020.00 |
| Sep 30, 2021 | 1.23 Mn |
| Jun 30, 2021 | 1.16 Mn |